CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Glycine reuptake inhibitor

drug class

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionSep 26, 2024
Entity authorityQ18345075 ↗
Source-derived summary

A glycine reuptake inhibitor (GRI) is a type of drug which inhibits the reuptake of the neurotransmitter glycine by blocking one or more of the glycine transporters (GlyTs). Examples of GRIs include bitopertin (RG1678), iclepertin (BI-425809), ORG-24598, ORG-25935, ALX-5407, and sarcosine, which are selective GlyT1 blockers, and ORG-25435 and N-arachidonylglycine, which are selective GlyT2 blockers. Some weak and/or non-selective GlyT blockers include amoxapine and ethanol (alcohol).

Editorial summary

“Glycine reuptake inhibitor” enters the record as drug class. Crown Archives preserves that source wording while asking what Glycine, reuptake and inhibitor can confirm, complicate or overturn.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current 66-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Glycine, reuptake and inhibitor.
Editorial analysis

Why this record matters

“Glycine reuptake inhibitor” is worth following because a concise public description often conceals a longer documentary argument. Here, Glycine, reuptake and inhibitor provides the most credible route into that argument.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 26, 2024. The linked authority identifier is Q18345075. None of the 0 selected statements returned an explicit reference.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Glycine reuptake inhibitor”, its source revision and the description used here.
  2. Expand the search: follow Glycine reuptake inhibitor primary sources, Glycine reuptake inhibitor archive and Glycine research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Glycine reuptake inhibitor”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Glycine reuptake inhibitor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.